YM087
Phase 3Small molecule
YM087 is one of 11 small molecule programs targeting Hyponatremia. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Hyponatremia
#DrugCompanyPhaseTrials
1Samsca
OtsukaApproved
Jardiance
Boehringer IngelheimApproved
Vaprisol
CCumberland Pharmaceuticals
Phase 3
Sterile Urea
PfizerPhase 2
Lixivaptan
PPalladio Biosciences
Phase 3
Satavaptan
SanofiPhase 3
SR121463B
SanofiPhase 3
YM087
CCumberland Pharmaceuticals
Phase 3
Conivaptan Hydrochloride
CCumberland Pharmaceuticals
Phase 3
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YM087. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCumberland Pharmaceuticals